The impact of adjuvant surgical treatment of nontuberculous mycobacterial pulmonary disease on prognosis and outcome.


Journal

Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633

Informations de publication

Date de publication:
16 Jun 2020
Historique:
received: 16 12 2019
accepted: 10 06 2020
entrez: 18 6 2020
pubmed: 18 6 2020
medline: 22 5 2021
Statut: epublish

Résumé

Lung resection in patients with nontuberculous mycobacterial pulmonary disease (NTM-PD) has been reported to be associated with favorable outcomes. However, little is known regarding the risk and prognostic factors for refractory and recurrent cases. We aimed to evaluate the overall impact and benefit of adjuvant lung surgery by comparing NTM-PD patients who underwent adjuvant lung resection with those treated exclusively with antibiotics. We also investigated the efficacy of serum IgA antibody against glycopeptidolipid (GPL) core antigen (GPL core antibody) to monitor disease activity and predict the recurrence of disease after adjuvant lung resection. We retrospectively evaluated the clinical characteristics and surgical outcomes of 35 patients surgically treated for NTM-PD. Furthermore, we compared surgically treated patients and control patients treated exclusively with antibiotics who were matched statistically 1:1 using a propensity score calculated from age, sex, body mass index, and radiologic features of disease. In the surgically treated patients, the median age was 58 (interquartile range, 47-65) years and 65.7% were female. Twenty-eight patients had Mycobacterium avium complex. Operations comprised four pneumonectomies, two bilobectomies, one bilobectomy plus segmentectomy, 17 lobectomies, two segmentectomies, and nine lobectomies plus segmentectomies. Postoperative complications occurred in seven patients (20%), there were no operative deaths, and 33 (94.3%) patients achieved negative sputum culture conversion. Refractory and recurrent cases were associated with remnant bronchiectasis, contralateral shadows, and positive acid-fast bacilli staining or culture. Of 28 statistically matched pairs, long-term sustained negative culture conversion was observed in 23 (82.2%) surgical group patients and in 14 (50.0%) non-surgical group patients (0.0438). The mortality rate was lower in the surgical group, but did not reach statistical significance (one in the surgical group and four in the non-surgical group, p = 0.3516). GPL core antibody was correlated with disease activity and recurrence. NTM-PD patients who underwent adjuvant lung resection experienced overall favorable outcomes and achieved sputum culture conversion more frequently. Long-term mortality may have been reduced by this procedure, and the level of GPL core antibody was shown to be a good clinical indicator of disease activity after surgery.

Sections du résumé

BACKGROUND BACKGROUND
Lung resection in patients with nontuberculous mycobacterial pulmonary disease (NTM-PD) has been reported to be associated with favorable outcomes. However, little is known regarding the risk and prognostic factors for refractory and recurrent cases. We aimed to evaluate the overall impact and benefit of adjuvant lung surgery by comparing NTM-PD patients who underwent adjuvant lung resection with those treated exclusively with antibiotics. We also investigated the efficacy of serum IgA antibody against glycopeptidolipid (GPL) core antigen (GPL core antibody) to monitor disease activity and predict the recurrence of disease after adjuvant lung resection.
METHODS METHODS
We retrospectively evaluated the clinical characteristics and surgical outcomes of 35 patients surgically treated for NTM-PD. Furthermore, we compared surgically treated patients and control patients treated exclusively with antibiotics who were matched statistically 1:1 using a propensity score calculated from age, sex, body mass index, and radiologic features of disease.
RESULTS RESULTS
In the surgically treated patients, the median age was 58 (interquartile range, 47-65) years and 65.7% were female. Twenty-eight patients had Mycobacterium avium complex. Operations comprised four pneumonectomies, two bilobectomies, one bilobectomy plus segmentectomy, 17 lobectomies, two segmentectomies, and nine lobectomies plus segmentectomies. Postoperative complications occurred in seven patients (20%), there were no operative deaths, and 33 (94.3%) patients achieved negative sputum culture conversion. Refractory and recurrent cases were associated with remnant bronchiectasis, contralateral shadows, and positive acid-fast bacilli staining or culture. Of 28 statistically matched pairs, long-term sustained negative culture conversion was observed in 23 (82.2%) surgical group patients and in 14 (50.0%) non-surgical group patients (0.0438). The mortality rate was lower in the surgical group, but did not reach statistical significance (one in the surgical group and four in the non-surgical group, p = 0.3516). GPL core antibody was correlated with disease activity and recurrence.
CONCLUSIONS CONCLUSIONS
NTM-PD patients who underwent adjuvant lung resection experienced overall favorable outcomes and achieved sputum culture conversion more frequently. Long-term mortality may have been reduced by this procedure, and the level of GPL core antibody was shown to be a good clinical indicator of disease activity after surgery.

Identifiants

pubmed: 32546152
doi: 10.1186/s12931-020-01420-1
pii: 10.1186/s12931-020-01420-1
pmc: PMC7298848
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

153

Subventions

Organisme : Japan Agency for Medical Research and Development
ID : JP19fk0108043
Organisme : Japan Agency for Medical Research and Development
ID : 20314279
Organisme : Japan Society for the Promotion of Science
ID : JP16K09537

Références

Sci Rep. 2016 Jul 04;6:29325
pubmed: 27373718
Int J Tuberc Lung Dis. 2015 Oct;19(10):1239-45
pubmed: 26459540
Intern Med. 2014;53(5):397-401
pubmed: 24583426
Am J Respir Crit Care Med. 2008 Apr 1;177(7):793-7
pubmed: 18079497
Gen Thorac Cardiovasc Surg. 2014 Aug;62(8):475-80
pubmed: 24740640
Antimicrob Agents Chemother. 2015;59(6):2972-7
pubmed: 25753634
Kekkaku. 2013 May;88(5):469-75
pubmed: 23882727
Eur Respir J. 2006 Aug;28(2):352-7
pubmed: 16611651
Am J Respir Crit Care Med. 2012 Mar 1;185(5):575-83
pubmed: 22199005
J Thorac Cardiovasc Surg. 2005 Jun;129(6):1258-65
pubmed: 15942565
J Korean Med Sci. 2008 Jun;23(3):397-401
pubmed: 18583873
Emerg Microbes Infect. 2019;8(1):1043-1053
pubmed: 31287781
Ann Thorac Surg. 1991 Nov;52(5):1108-11; discussion 1112
pubmed: 1953131
Am J Respir Crit Care Med. 2011 Feb 1;183(3):405-10
pubmed: 20833823
Am J Respir Crit Care Med. 1997 Aug;156(2 Pt 2):S1-25
pubmed: 9279284
Am J Respir Crit Care Med. 2007 Feb 15;175(4):367-416
pubmed: 17277290
Clin Chest Med. 2015 Mar;36(1):13-34
pubmed: 25676516
Ann Thorac Surg. 2013 Jul;96(1):287-91
pubmed: 23618520
Emerg Infect Dis. 2016 Jun;22(6):1116-7
pubmed: 27191735
Clin Diagn Lab Immunol. 2005 Jan;12(1):44-51
pubmed: 15642983
Clin Infect Dis. 2017 Jul 15;65(2):244-251
pubmed: 28369361
BMC Infect Dis. 2015 Feb 19;15:76
pubmed: 25887191
Int J Tuberc Lung Dis. 2015 Jan;19(1):97-103
pubmed: 25519798
Ann Thorac Surg. 2012 Apr;93(4):1033-9; discussion 1039-40
pubmed: 22386091
Thorax. 2000 Aug;55(8):717-9
pubmed: 10899252
Ann Am Thorac Soc. 2016 Nov;13(11):1904-1911
pubmed: 27513168
Ann Thorac Surg. 2004 Aug;78(2):399-403
pubmed: 15276484
Eur J Cardiothorac Surg. 2002 Feb;21(2):314-8
pubmed: 11825742
Eur J Clin Microbiol Infect Dis. 2014 Mar;33(3):347-58
pubmed: 23979729
Respir Res. 2015 Dec 03;16:145
pubmed: 26635226
Curr Opin Infect Dis. 2012 Apr;25(2):218-27
pubmed: 22327466
Eur Respir J. 2016 Jan;47(1):45-68
pubmed: 26699723
Clin Infect Dis. 2011 Mar 1;52(5):565-71
pubmed: 21292659
Bioinformatics. 2018 Sep 15;34(18):3094-3100
pubmed: 29750242
Ann Am Thorac Soc. 2016 Nov;13(11):1956-1961
pubmed: 27599038
Clin Infect Dis. 2017 Feb 1;64(3):309-316
pubmed: 28011608

Auteurs

Kiyoharu Fukushima (K)

Department of Respiratory Medicine, National Hospital Organization Osaka Toneyama Medical Center, 5-1-1 Toneyama Toyonaka, Osaka, Japan.
Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, Japan.

Mari Miki (M)

Department of Respiratory Medicine, National Hospital Organization Osaka Toneyama Medical Center, 5-1-1 Toneyama Toyonaka, Osaka, Japan.

Yuki Matsumoto (Y)

Department of Infection Metagenomics, Genome Information Research Center, Research Institute for Microbial Diseases (RIMD), Osaka University, 3-1 Yamadaoka, Suita, Osaka, Japan.

Emi Uda (E)

Department of Respiratory Medicine, National Hospital Organization Osaka Toneyama Medical Center, 5-1-1 Toneyama Toyonaka, Osaka, Japan.

Yuji Yamamoto (Y)

Department of Respiratory Medicine, National Hospital Organization Osaka Toneyama Medical Center, 5-1-1 Toneyama Toyonaka, Osaka, Japan.

Yuya Kogita (Y)

Department of General Thoracic Surgery, National Hospital Organization Osaka Toneyama Medical Center, 5-1-1 Toneyama Toyonaka, Osaka, Japan.

Yuko Kagawa (Y)

Department of General Thoracic Surgery, National Hospital Organization Osaka Toneyama Medical Center, 5-1-1 Toneyama Toyonaka, Osaka, Japan.

Takanori Matsuki (T)

Department of Respiratory Medicine, National Hospital Organization Osaka Toneyama Medical Center, 5-1-1 Toneyama Toyonaka, Osaka, Japan.

Hiroyuki Kagawa (H)

Department of Respiratory Medicine, National Hospital Organization Osaka Toneyama Medical Center, 5-1-1 Toneyama Toyonaka, Osaka, Japan.

Yohei Oshitani (Y)

Department of Respiratory Medicine, National Hospital Organization Osaka Toneyama Medical Center, 5-1-1 Toneyama Toyonaka, Osaka, Japan.

Daisuke Motooka (D)

Department of Infection Metagenomics, Genome Information Research Center, Research Institute for Microbial Diseases (RIMD), Osaka University, 3-1 Yamadaoka, Suita, Osaka, Japan.

Kazuyuki Tsujino (K)

Department of Respiratory Medicine, National Hospital Organization Osaka Toneyama Medical Center, 5-1-1 Toneyama Toyonaka, Osaka, Japan.

Kenji Yoshimura (K)

Department of Respiratory Medicine, National Hospital Organization Osaka Toneyama Medical Center, 5-1-1 Toneyama Toyonaka, Osaka, Japan.

Keisuke Miki (K)

Department of Respiratory Medicine, National Hospital Organization Osaka Toneyama Medical Center, 5-1-1 Toneyama Toyonaka, Osaka, Japan.

Akio Hayashi (A)

Department of General Thoracic Surgery, National Hospital Organization Osaka Toneyama Medical Center, 5-1-1 Toneyama Toyonaka, Osaka, Japan.

Shota Nakamura (S)

Department of Infection Metagenomics, Genome Information Research Center, Research Institute for Microbial Diseases (RIMD), Osaka University, 3-1 Yamadaoka, Suita, Osaka, Japan.

Seigo Kitada (S)

Department of Respiratory Medicine, Yao Tokusyuukai General Hospital, 1-17 Wakakusa-cho, Yao, Osaka, Japan.

Yukiyasu Takeuchi (Y)

Department of General Thoracic Surgery, National Hospital Organization Osaka Toneyama Medical Center, 5-1-1 Toneyama Toyonaka, Osaka, Japan.

Hiroshi Kida (H)

Department of Respiratory Medicine, National Hospital Organization Osaka Toneyama Medical Center, 5-1-1 Toneyama Toyonaka, Osaka, Japan. kida.hiroshi.sv@mail.hosp.go.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH